Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Avacta Group plc ( (GB:AVCT) ) is now available.
Avacta Group plc plans to raise approximately £10 million through a discounted equity placing and subscription of around 15.9 million new shares at 63 pence, with Zeus Capital acting as sole bookrunner. The net proceeds are expected to fund research and development and general working capital, extending the company’s cash runway into early Q1 2027 and beyond the initial Phase 1a data readout for AVA6103.
The fundraising supports the rapid clinical advancement of Avacta’s pipeline, including Phase 1b expansion cohorts of faridoxorubicin (AVA6000) across several cancer indications and the imminent dosing of AVA6103, a pre|CISION-based exatecan peptide drug conjugate. Management aims to retain full rights to AVA6103 at least until initial Phase 1a data in late 2026, while director participation in the subscription signals board confidence and positions the company for future partnering discussions around its lead assets and next-generation candidate AVA6207.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Group plc is a clinical-stage biopharmaceutical and life sciences company developing oncology therapies based on its proprietary pre|CISION tumor-activated drug delivery platform. The technology underpins peptide drug conjugates designed to concentrate highly potent cancer payloads in the tumor microenvironment, aiming to improve efficacy while reducing systemic toxicity versus traditional antibody drug conjugates.
Average Trading Volume: 1,647,710
Technical Sentiment Signal: Buy
Current Market Cap: £304M
For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.